Top Markets
#1 Siren Siren +39.86%
#2 RedStone RedStone +23.17%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.68%
#4 Perle Perle +15.69%
#5 Ocean Protocol Ocean Protocol +15.26%
#6 KUB Coin KUB Coin +14.31%
#7 Verus Coin Verus Coin +13.51%
#8 Cysic Cysic +10.93%
#9 Nosana Nosana +10.32%
#10 Quack AI Quack AI +10.31%
Coin of the day
Siren Siren
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
VistaGen Therapeutics, Inc. VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc.

VTGN
Kedudukan dalam Saham #31938
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity... VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
Harga Saham
$0.2619
Disegerakkan terakhir: 2026-08-17
Modal Pasaran
$11.62M
Perubahan (1 hari)
-2.13%
Perubahan (1 tahun)
-92.30%
Negara
US
Perdagangan VistaGen Therapeutics, Inc. (VTGN)

Kategori

Healthcare
Hasil untuk VistaGen Therapeutics, Inc. (VTGN)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada VistaGen Therapeutics, Inc., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi VistaGen Therapeutics, Inc. dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR